Myopharm is an IND stage biotechnology company focused on developing first in class, novel therapeutics for the treatment and prevention of Type 2 diabetes. 
Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric dual combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics. 

Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza™ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza™ to market by 2027.

https://www.myopharm.com

Myopharm Limited

Org chart

Teams

Offices

Similar companies